



NDA 21-751/S-008

**SUPPLEMENT APPROVAL**

Hameln Pharmaceuticals GmbH  
B & H Consulting Services, Inc.  
Attention: Elizabeth N. Dupras, RAC  
Senior Project Manager  
50 Division Street, Suite 206  
Somerville, NJ 08876

Dear Ms. Dupras:

Please refer to your Supplemental New Drug Application (sNDA) dated August 18, 2010, received August 19, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Pentetate Zinc Trisodium (Zn-DTPA) injection.

We acknowledge receipt of your amendments dated February 14, July 25, September 6, 20, and November 15, 2012.

The September 20, 2012, submission constituted a complete response to our August 15, 2012, action letter.

This supplemental new drug application was in response to the Agency's request on June 4, 2010 for a Prior Approval Supplement (PAS) to provide labeling in Physician's Labeling Rule (PLR) format.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Frank Lutterodt, Regulatory Project Manager, at (301) 796-4251.

Sincerely,

*{See appended electronic signature page}*

Rafel Dwaine Rieves, M.D.  
Director  
Division of Medical Imaging Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

ENCLOSURE(S):  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RAFEL D RIEVES  
03/21/2013